ATHA - Athira Pharma Inc Debt to Book Capitalization Ratio

Graphic logo of athira.com (ATHA)

Athira Pharma, Inc. (ATHA) is developing advanced neural connection regeneration methods to combat Parkinson's and Alzheimer's diseases. The immense potential of this market drives colossal demand for new pharmaceuticals. The company's revenue is based on the commercialization of small molecules for brain restoration. Analyzing this chart on GURU.Markets, we see that the debt-to-capitalization ratio is 0.03.

Athira Pharma Corp (ATHA) - Debts to Book Value from 07/04/2022 to 01/12/2026
Signature product of Athira Pharma Inc

Assess the financial stability of Athira Pharma, Inc. (ATHA) through the balance of debt and equity. This metric compares total liabilities to the book value of equity to determine the degree of leverage. By analyzing the current ratio of liabilities to book capitalization, an investor can discern the business's level of dependence on creditors. For an innovator in neuron regeneration, low debt is critically important, as it ensures the autonomy of costly Alzheimer's disease research.

Who Athira Pharma, Inc. competes with

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|VKTX (Viking Therapeutics) - Debts to Book Capitalization|Debts to Book Capitalization supernus.com (SUPN)|Debt to Book Value Catalyst Pharmaceuticals, Inc.|Debt to Book Capital Denali (DNLI)|Debts to Book Capitalization Harmony Pharma|Debt to Net Assets Ratio Biohaven Corp BHVN|Debts to Book Capitalization AMLX (Amylyx Pharmaceuticals)|TRVI: Debts to Net Assets|Debt to Book Capitalization Ratio Praxis Precision Medicines, Inc. PRAX|Anavex (AVXL) - Debt to Net Assets Ratio|CBLL (CeriBell Corp) - Debts to Book Capitalization|Debts to Book Capitalization prothena.com (PRTA)|Alector, Inc. (ALEC) - Debt to Book Value|Debt to Net Assets Ratio ANNX (annexonbio.com)|Omeros (OMER) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Neurogene Inc NGNE|Debts to Book Capitalization AC Immune Corp (ACIU)|VYGR - Debt to Net Assets Ratio|NMRA: Debts to Book Capitalization|SCLX (scilexholding.com) - Debts to Book Capitalization|TVGN - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ACOG|Debt to Book Capitalization Ratio CGTX (Cognition Therapeutics)|Debt to Book Value Inhibikase Pharma (IKT)|Debts to Book Capitalization SAVA (Cassava Sciences, Inc.)|ASRT - Debts to Book Capitalization|Debt to Book Value Coya (COYA)|VTGN - Debt to Net Assets Ratio|ovidrx.com - Debts to Book Capitalization|ABOS (Acumen Pharmaceuticals, Inc) - Debts to Net Assets|Debt to Book Capitalization Ratio CervoMed Inc. (CRVO)|Debt to Book Value Ratio Alterity Therapeutics Ltd|Debts to Book Capitalization CLNN (Clene Inc.)|Debt to Book Value pepgen.com PEPG|Debt to Book Value JUNS|Debts to Net Assets Relmada Corp RLMD|Annovis Bio, Inc. - Debts to Book Capitalization|Grace Therapeutics, Inc. (GRCE) - Debts to Book Capitalization|AIFF - Debt to Book Value|Klotho Neurosciences (KLTO) - Debt to Book Capital|NRSN - Debts to Book Capitalization|Debt to Net Assets Ratio Reviva Pharmaceuticals, Inc.|Debts to Book Capitalization MTVA|Debts to Book Capitalization NRXS (neuraxis.com)|HSDT - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Passage Bio Inc. PASG|NEUP (Neuphoria) - Debts to Book Capitalization|Minerva (NERV) - Debts to Book Value|ADXN: Debt to Book Value|ALZN (Alzamend Neuro) - Debts to Book Capitalization|CYCN - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio PTIX|Pasithea Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value cortigent.com (CRGT)|Debts to Book Capitalization ATXI (Avenue Therapeutics)|BCLI - Debts to Book Capitalization|Debt to Book Value Cara Therapeutics CARA|CHRO - Debt to Book Capital|Debts to Book Capitalization eliemtx.com ELYM|Intra-Cellular Therapies, Inc. (ITCI) - Debt to Net Assets Ratio|LBPH: Debts to Book Capitalization|Debts to Net Assets MRNS|NKGen Biotech (NKGN) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio NeuroBo Pharmaceuticals Inc (NRBO)|Debts to Book Capitalization SAGE (Sage Therapeutics, Inc)|SNPX - Debts to Book Capitalization|Debt to Book Value Trevena, Inc. (TRVN)|VIGL: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Anew Medical (WENA)|Cerevel Therapeutics Inc (CERE) - Debts to Book Capitalization Ratio